In my August 14th Brookfield Asset Management (BAM) stock analysis I disclose the purchase of additional BAM shares through various accounts. In that post, I conclude: 'I have no interest in investing in cryptocurrencies, SPACs, or complex derivative products. I do, however, want exposure to alternative assets thus my reason for investing in BAM.' After [...]
I have been a Visa (V) shareholder almost from the day it went public on March 18, 2008. Over the years I have also increased my exposure. My most recent purchase was made in early March 2022 at which time I acquired shares at ~$195. The number of shares acquired was not meaningful so I [...]
A year has elapsed since I last reviewed Otis Worldwide Corporation (OTIS). At the time, I envisioned a broad market sell-off would lead to a more attractive valuation. Following that post, OTIS's share price skyrocketed and its valuation deteriorated. In early February 2022, I took a quick look at OTIS but still did not like [...]
In my October 20, 2021 post, I disclose a new 30 share position in Intuitive Surgical (ISRG) in a 'Core' account in the FFJ Portfolio and conclude that post by stating that 'Despite shares being grossly overvalued, I think ISRG will be a far more valuable company several years into the future.' I followed [...]
On April 21, 2022 I published my Danaher (DHR) - Creating Long-Term Shareholder Value post. In that post, I touch upon why I deem it to be an attractive long-term investment. I conclude by stating my intent to acquire additional shares even though its valuation is slightly less attractive than at the time of [...]
Danaher (DHR) is creating long-term shareholder value. Over a 10-year timeframe, the average annual total return with the reinvestment of dividends is 22.07% and 21.73% without the reinvestment of dividends. In contrast, the returns from the S&P500 are 14.69% and 13.65% (source: www.tickertech.com). Despite viewing DHR's valuation to be somewhat rich, I initiated a small [...]
I first reviewed LMT in this November 20, 2020 post at which time I disclosed the initiation of a 200 share position @ ~$369/share in one of the 'Core' accounts in the FFJ Portfolio. In subsequent posts (see The FFJ Archives) I disclose additional purchases which have brought my exposure to 455 shares. In my [...]
I last reviewed Goldman Sachs' (GS) in my January 19, 2022 post at which time I conclude GS's valuation to be attractive. I had to severely curtail my additional GS investment, however, because I require funds to cover tax obligations following the completion of our 2021 tax returns. GS released Q1 2022 results on April [...]
My interest has been piqued in that FedEx's (FDX) current ~$201.50 share price is well below the ~$320 52 week high. In this review, I touch upon why FedEx's valuation is appealing and why I acquired a few additional shares on April 8, 2022 at ~$201.50/share. I last reviewed FDX in this March 25, 2021 [...]
I last reviewed HD in this June 7, 2021 post at which time I concluded shares were too richly valued. HD's share price subsequently ballooned to ~$420 toward the end of 2021. It has, however, now retraced to ~$303. This share price pullback piqued my interest and based on my analysis, I am now an [...]